Insider Selling: Alumis (NASDAQ:ALMS) Insider Sells $67,823.64 in Stock

Posted by Brian Himes on Aug 5th, 2026

Alumis Inc. (NASDAQ:ALMS – Get Free Report) insider Mark Christopher Bradley sold 2,572 shares of the stock in a transaction on Monday, August 3rd. The stock was sold at an average price of $26.37, for a total transaction of $67,823.64. Following the sale, the insider directly owned 48,533 shares of the company’s stock, valued at $1,279,815.21. This represents a 5.03% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Alumis Price Performance

NASDAQ ALMS remained flat at $27.12 on Wednesday. 629,130 shares of the company were exchanged, compared to its average volume of 2,037,268. The stock’s fifty day moving average price is $25.26 and its two-hundred day moving average price is $25.20. The firm has a market cap of $3.46 billion, a price-to-earnings ratio of -13.70 and a beta of -0.69. Alumis Inc. has a 12-month low of $3.76 and a 12-month high of $31.35.

Alumis (NASDAQ:ALMS – Get Free Report) last released its quarterly earnings results on Thursday, May 14th. The company reported ($0.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.73) by ($0.01). The firm had revenue of $1.74 million during the quarter, compared to analyst estimates of $2.10 million. Alumis had a negative net margin of 2,825.70% and a negative return on equity of 88.79%. Research analysts anticipate that Alumis Inc. will post -2.87 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on the stock. Guggenheim raised their price target on shares of Alumis from $32.00 to $34.00 and gave the stock a “buy” rating in a research note on Friday, May 15th. Citigroup restated a “buy” rating on shares of Alumis in a report on Tuesday, May 19th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Alumis in a research report on Tuesday, July 7th. Morgan Stanley reiterated an “overweight” rating and issued a $39.00 price target on shares of Alumis in a research note on Friday, May 15th. Finally, Wells Fargo & Company boosted their price target on shares of Alumis from $49.00 to $51.00 and gave the stock an “overweight” rating in a research report on Friday, May 15th. One equities research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $40.30.

View Our Latest Report on ALMS

Institutional Investors Weigh In On Alumis

Several large investors have recently made changes to their positions in the stock. MPM Bioimpact LLC bought a new position in shares of Alumis in the fourth quarter valued at $23,443,000. Janus Henderson Group PLC acquired a new stake in Alumis in the first quarter valued at $46,790,000. Orbimed Advisors LLC bought a new position in shares of Alumis in the 2nd quarter valued at about $5,779,000. Woodline Partners LP grew its position in shares of Alumis by 809.7% in the 3rd quarter. Woodline Partners LP now owns 1,751,150 shares of the company’s stock valued at $6,987,000 after acquiring an additional 1,558,660 shares during the period. Finally, Samsara Biocapital LLC increased its stake in shares of Alumis by 47.0% during the 2nd quarter. Samsara Biocapital LLC now owns 4,801,370 shares of the company’s stock worth $14,404,000 after purchasing an additional 1,534,872 shares during the last quarter.

About Alumis

(Get Free Report)

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.